ストックスクリーナーアプリを入手
16.43
0.18%
-0.03
アフターアワーズ：
16.42
-0.010
-0.06%
前日終値:
$16.46
開ける：
$16.61
24時間の取引高:
1.02M
Relative Volume:
1.00
時価総額：
$1.83B
収益：
$-665.00K
当期純損益:
$-144.74M
株価収益率:
-10.58
EPS:
-1.5527
ネットキャッシュフロー:
$-123.48M
1週間 パフォーマンス:
+0.74%
1か月 パフォーマンス:
+9.90%
6か月 パフォーマンス:
+24.09%
1年 パフォーマンス:
+219.03%
1日の値動き範囲:
$15.98
$16.94
1週間の範囲:
$15.39
$16.94
52週間の値動き範囲:
$4.20
$18.61
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
名前
Amylyx Pharmaceuticals Inc
セクター
電話
617-682-0917
住所
55 CAMBRIDGE PARKWAY, CAMBRIDGE
Compare AMLX vs TAK, ZTS, TEVA, HLN, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
16.43 | 1.83B | -665.00K | -144.74M | -123.48M | -1.5527 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-03 | 開始されました | Stifel | Buy |
| 2025-07-10 | 再開されました | Goldman | Buy |
| 2025-06-24 | 開始されました | Guggenheim | Buy |
| 2025-06-17 | 開始されました | Citigroup | Buy |
| 2025-05-30 | 開始されました | TD Cowen | Buy |
| 2025-04-07 | アップグレード | Mizuho | Neutral → Outperform |
| 2024-11-18 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-03-18 | ダウングレード | Mizuho | Buy → Neutral |
| 2024-03-11 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-03-08 | ダウングレード | Goldman | Buy → Neutral |
| 2024-01-03 | 開始されました | Robert W. Baird | Outperform |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-07-24 | アップグレード | Goldman | Neutral → Buy |
| 2023-03-31 | 開始されました | Mizuho | Buy |
| 2023-01-05 | 開始されました | BofA Securities | Buy |
| 2022-05-25 | 開始されました | Citigroup | Buy |
| 2022-04-01 | ダウングレード | Goldman | Buy → Neutral |
すべてを表示
Amylyx Pharmaceuticals Inc (AMLX) 最新ニュース
Amylyx Investors To Get $6.5M In ALS Drug Settlement - Law360
Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia - Business Wire
Sarepta, Amylyx and Neumora look ahead to key catalysts as Q1 earnings roll in - BioSpace
MSN Money - MSN
H.C. Wainwright raises Amylyx stock price target to $34 on trial confidence - Investing.com
AMLX Stock Price, Quote & Chart | AMYLYX PHARMACEUTICALS INC (NASDAQ:AMLX) - ChartMill
Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 - BioSpace
Amylyx’s ORION Trial in Progressive Supranuclear Palsy Reaches Completion: What Investors Should Watch - TipRanks
Press Release: Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 - Moomoo
Amylyx sets May 7 earnings report, 8 a.m. ET webcast - Stock Titan
Amylyx Pharmaceuticals (AMLX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Bank of America Securities Reaffirms Their Buy Rating on Amylyx Pharmaceuticals Inc (AMLX) - The Globe and Mail
Mizuho Adjusts Price Target on Amylyx Pharmaceuticals to $21 From $19, Maintains Outperform Rating - marketscreener.com
BofA raises Amylyx Pharmaceuticals stock price target on model updates By Investing.com - Investing.com Nigeria
BofA raises Amylyx Pharmaceuticals stock price target on model updates - Investing.com
Mizuho raises Amylyx stock price target on lower expense outlook By Investing.com - Investing.com India
Mizuho Forecasts Strong Price Appreciation for Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Mizuho raises Amylyx stock price target on lower expense outlook - Investing.com
Amylyx Pharmaceuticals Q3 2025 Earnings Preview - MSN
Amylyx Pharmaceuticals, Inc. ($AMLX) Co-CEO and Director 2025 Pay Revealed - Quiver Quantitative
[ARS] Amylyx Pharmaceuticals, Inc. SEC Filing - Stock Titan
Executive pay, avexitide milestones and 2026 vote at Amylyx (NASDAQ: AMLX) - Stock Titan
AMLX (Amylyx Pharmaceuticals Inc.) reports narrower Q4 2025 loss than estimates, shares climb 3.55 percent on positive investor sentiment.Revenue Per Share - Cổng thông tin điện tử tỉnh Lào Cai
AMLX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Amylyx (AMLX) Stock Stop Limit Order (-3.24%) 2026-04-20Pro Level Trade Signals - Xã Thanh Hà
Stock Traders Purchase High Volume of Call Options on Amylyx Pharmaceuticals (NASDAQ:AMLX) - MarketBeat
Amylyx Pharmaceuticals stock hits 52-week high at 17.5 USD By Investing.com - Investing.com Australia
Analysts Offer Insights on Healthcare Companies: Ceribell, Inc. (CBLL), ANI Pharmaceuticals (ANIP) and Amylyx Pharmaceuticals Inc (AMLX) - The Globe and Mail
Amylyx Pharmaceuticals (NASDAQ:AMLX) Reaches New 12-Month HighShould You Buy? - MarketBeat
Amylyx Pharmaceuticals stock hits 52-week high at 17.5 USD - Investing.com
Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Amylyx Pharmaceuticals Sets Up Q3 Phase 3 Avexitide Data Readout, Eyes Potential 2027 Launch - Yahoo Finance
Bull Run: What is Amylyx Pharmaceuticals Incs book value per share2026 Dividend Review & Daily Profit Maximizing Tips - baoquankhu1.vn
Amylyx Pharmaceuticals, Inc. (AMLX) stock price, news, quote and history - Yahoo Finance Singapore
Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Finviz
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Layoff Watch: Is Amylyx Pharmaceuticals Inc stock a smart retirement pick2026 Patterns & AI Powered Trade Plan Recommendations - baoquankhu1.vn
AMLX SEC FilingsAmylyx Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference - BioSpace
Buy Rating on Amylyx: De-Risked Avexitide Phase III Study and Significant PBH Market Opportunity Support 2027 Launch Potential - TipRanks
A Look At Amylyx Pharmaceuticals (AMLX) Valuation As Avexitide Hits A Key Phase 3 LUCIDITY Milestone - Sahm
Amylyx Pharmaceuticals Inc (AMLX) Shares Up 6.66% on Apr 6 - GuruFocus
Amylyx Pharmaceuticals Shares Rise 6.9% on Positive News - National Today
Amylyx Pharmaceuticals Inc (AMLX) 財務データ
収益
当期純利益
現金流量
EPS
0.67%
2.13%
大文字化:
|
ボリューム (24 時間):